- Lannett Company (NYSEMKT:LCI) announces plans to co-develop a generic insulin pharmaceutical product for sale in the U.S. with its strategic partner in China, YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Lannett, who will have exclusive marketing rights to the late-stage candidate, will take over the remaining clinical and regulatory work to support an FDA filing.
- According to IMS, the U.S. insulin market is greater than $21B.